News & Updates
Featured
Experience in healthcare is about things like "how long you wait." Outcome is the "result" of your treatment. For patients, this can mean the difference between life and death.
It is simply devastating for cancer patients to have targeted therapy drugs withdrawn – especially when it is unknown when a replacement will become available, as in the case of Mobocertinib. It is essential that alternative therapies are made available as soon as possible, to help people live well, for longer.
Created in response to feedback from patients needing a specific tool to help them, Your Health Companion for peritoneal mesothelioma has been co-developed with specialist peritoneal nurses, clinicians, and patient advocacy groups to ensure it meets the needs of the user and empowers patients to take an active part in their care.
Your Health Companion will be used to capture real-world patient experience from patients across the country, of what it is like to be diagnosed, be living with and treated or cared for if you have mesothelioma in the UK.
The article in Nursing Times, ‘Digitising Cancer Care: using electronic patient-reported outcomes measures’, was extremely positive. Digitising cancer care can lead to dramatic improvements and benefits for both patients and healthcare teams(1)….
Monitoring the side-effects of treatment is very important for both patients and healthcare professionals. Being informed and having honest and open conversations about treatment side-effects helps patients get the best medicine for them.
There is an update to Your Health Companion available to download from the App Store and Google Play. If you use your computer to access the app, you will automatically see the new version of the app when you next sign in.
Cancer charities are choosing Your Health Companion to give patients more control of their care and to put the ‘patient voice’ at the centre of research to assess cancer medicines and healthcare provision. The aim is that this will lead to significant improvements in assessment of new treatment and the delivery of NHS services.
A recent Cancer Research UK report states that more than 500,000 people in the UK will be diagnosed with cancer by 2040 – putting overwhelming strain on the NHS and potentially lives at risks. But not all is doom and gloom. Digital integration may be the answer
The Christie at Macclesfield’s Catherine Fensom joins DaSH Global to ensure the digital integration of new cancer service, Your Health Companion, into the delivery of NHS cancer services to radically improve patient care.
Are you looking for a new world - to undertake Real World Evidence (RWE) research through a more integrated digital health approach – providing tangible benefits over existing observational study methods? If so, you are probably looking for direction and the right vehicle/s to help you get there. Then, maybe, this old joke is more helpful than you might think!
We really don't believe in re-inventing the wheel! We're even re-using this slide we found on the internet on "The Evolution of Digital Health" as we think it's so apposite. Its time to ensure we use and implement all the good thinking that has gone before.
DaSH-Global is an agency based in the UK which specialises in real-world digital methodologies through a vision of building collaborative "disruptive" transformational research models from "joined up" health care ( linking into health service infrastructures).
Lung Cancer Nursing UK (LCNUK), the charity that supports nurses specialising in the care of people with lung cancer, launches ‘Your Health Companion’.
The free digital diary has been specifically developed for people living with mesothelioma, to enable them to record how they are feeling, their quality of life and symptoms, rate the experience of the care they receive and keep track of expenses connected with their care.
As the digital health markets continue to converge, new products and services must be aligned to healthcare policy, regulatory requirements, research needs and, most importantly, a more demanding public.
DaSH Global have been collaborating with Manchester University and Greater Manchester Mental Health Trust in the development of the Digital Assessment Xchange in Mild Cognative Impairment, (MCI-DAX).
DaSH Global are collaborating with the Head of Services, Liz Darlison, (MBE), at Mesothelioma UK in the development of the Digital Assessment Xchange in Mesothelioma, (Meso-DAX).
Everyone these days it seems, wants to describe their idea as a 'disruptive innovation'. It provides cachet. If your businesses is not disruptive what is it? By claiming it, we're all claiming legitimacy, and even the power to unseat behemoths. It all begins with an idea.
Amongst industry experts there is almost total agreement that digital health in 2020 is headed for much greater integration into everyday healthcare delivery.
DaSH Global in collaboration with Mesothelioma UK have undertaken a prospective cross-sectional study in the UK collecting both Clinical and Patient Reported Outcomes data from a total of 503 Mesothelioma patients.
It has been good to take a look back at an article I contributed to with NICE and IQWIG in 2014: “Is Pharma doing enough to maximise real world evidence?”. It was interesting to compare “where we were then” to “where we are now” – or should we say, “where we want to be now”?